You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Severe eosinophilic asthma phenotype

Go to Top Close

Severe asthma is a complex heterogeneous disease affecting up to 10% of people with asthma.1 Recent advances have increased our understanding of the role of eosinophils in the disease.

Evidence shows that patients with severe asthma are comprised of different phenotypes; one example is an eosinophilic asthma phenotype which has been shown to be associated with asthma severity, late onset disease and refractoriness. 2

The role of IL-5 and eosinophils

IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation, and survival of eosinophils.3

Eosinophils play a role in airway inflammation and exacerbation risk, and eosinophilia is associated with increased symptoms and a greater likelihood of exacerbations.4,5

Nucala targets IL-5

Nucala, which is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents, and children aged 6 years and older, targets IL-5.6

Raised blood eosinophils have been validated as a biomarker for the patients most likely to benefit from Nucala.7 Patients with blood eosinophils ≥150 cells/μL at initiation of treatment or ≥300 cells/μL in the prior 12 months are predicted to respond to Nucala.6,7

In patients with mean blood eosinophils 290 cells/μL at baseline, Nucala reduced blood eosinophils by 84% at 4 weeks.6

Footnotes:

  • Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.6
  • Only Nucala 100mg SC is licensed in patients aged 12 years and older.
  • Only Nucala 40mg SC is licensed in patients aged 6–11 years.

References:

  1. Moore WC, et al. J Allergy Clin Immunol 2007; 119:405–413.
  2. Walford H and Doherty T. J Asthma Allergy 2014; 11 [7]: 53-65.
  3. Weller PF, Spencer LA. Nat Rev Immunol 2017; 17:746–760.
  4. Malinovschi A, et al. J Allergy Clin Immunol 2013; 132:821–827.
  5. Wenzel S. Am J Respir Crit Care Med 2005;172(2):149–160.
  6. Nucala SmPC, 2019. Available at www.medicines.ie Last accessed January 2019.
  7. Ortega HG et al. Lancet Respir Med 2016; 4:549–556.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse events can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Copyright © 2019 GlaxoSmithKline Group of Companies. All rights reserved.
Nucala is a registered trademark of the GlaxoSmithKline Group of Companies.